Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
March 16, 2023 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
March 14, 2023 16:30 ET
|
Affimed N.V.
An oral presentation on the safety and efficacy from the AFM13 phase 2 monotherapy clinical study (“REDIRECT”) in patients with CD30-positive relapsed or refractory (R/R) peripheral T-cell lymphoma...
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
March 09, 2023 05:00 ET
|
Affimed N.V.
PLZEN, Czech Republic, March 09, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced...
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
February 22, 2023 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
February 21, 2023 05:00 ET
|
Affimed N.V.
PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced...
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
February 08, 2023 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
January 09, 2023 06:30 ET
|
Affimed N.V.
AFM13 combination with Artiva’s AB-101 NK cells: Received written feedback to pre-investigational new drug (IND) meeting request which supports plan for IND filing in H1 2023 and initiation of...
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
December 22, 2022 06:30 ET
|
Affimed N.V.
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of...
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting
December 12, 2022 10:00 ET
|
Affimed N.V.
AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid...
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
December 10, 2022 15:00 ET
|
Affimed N.V.
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral T cell lymphoma (r/r PTCL) patients with a differentiated safety profile AFM13...